Sponsor:
University of Cincinnati
Code:
NCT06933095
Conditions
Eldery People
Cognitive Decline
Memory Decline
DHA CNS Delivery
Eligibility Criteria
Sex: All
Age: 55 - 70+
Healthy Volunteers: Not accepted
Interventions
LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)
Brief summary:
Conditions
Eldery People
Cognitive Decline
Memory Decline
DHA CNS Delivery
Study ID
NCT06933095
Start date
Sep 15, 2024
Status verified date
Aug, 2026
Completion date
Sep 15, 2029
Anticipated
Primary completion date
Sep 15, 2029
Anticipated
Eligibility Criteria
Sex: All
Age: 55 - 70+
Healthy Volunteers: Not accepted
Enrollment
153 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Basic Science
Arms
placebo comparator: Placebo (mixture of olive oil, corn oil, palm oil)
active comparator: fish oil
experimental: LPC-EPA+DHA (investigational agent) capsules containing omega-3 fatty acids EPA and DHA esterified t
Interventions
LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)
Primary outcome measure
Central contacts
Locations
University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience
Recruiting
Cincinnati, Ohio, United States, 45219
Contacts
Sponsor
University of Cincinnati
Last update posted
Aug 19, 2026
Last verified
Aug, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Cincinnati on 2026-08-19.